MS-DRG 848MDC 17
CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITHOUT CC/MCC
Related MS-DRGs in MDC 17
820LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH MCC821LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH CC822LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITHOUT CC/MCC823LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER PROCEDURES WITH MCC824LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER PROCEDURES WITH CC825LYMPHOMA AND NON-ACUTE LEUKEMIA WITH OTHER PROCEDURES WITHOUT CC/MCC826MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURES WITH MCC827MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURES WITH CC828MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURES WITHOUT CC/MCC829MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH OTHER PROCEDURES WITH CC/MCC
Frequently asked questions
What is MS-DRG 848?
CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITHOUT CC/MCC
What is the relative weight of MS-DRG 848?
MS-DRG 848 has a relative weight of 0.8494 for FY2026, which reflects the relative resource intensity of cases grouped into it.
What is the average length of stay for MS-DRG 848?
The geometric mean length of stay for MS-DRG 848 is 2.6 days.
What Major Diagnostic Category (MDC) does MS-DRG 848 belong to?
MS-DRG 848 falls under MDC 17: Myeloproliferative Diseases and Disorders, and Poorly Differentiated Neoplasms.
MS-DRG data (FY2026) from the CMS Inpatient Prospective Payment System (IPPS) final rule. Always verify codes with authoritative sources before making billing decisions.